Status:
COMPLETED
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
Lead Sponsor:
KoBioLabs
Conditions:
Psoriatic Plaque
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
Eligibility Criteria
Inclusion
- Male or female, aged 18 to 75 years (inclusive)
- Have a diagnosis of plaque type psoriasis for ≥ 6 months
- Must have chronic plaque type psoriasis of moderate severity
- All subjects must agree and commit to the use of a reliable contraceptive regimen.
Exclusion
- Current diagnosis of forms of psoriasis other than chronic plaque type only
- Drug-induced psoriasis
- Other inflammatory skin disease that may confound the evaluation of plaque psoriasis
- Failed 2 or more systemic treatments for plaque psoriasis
- Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit
Key Trial Info
Start Date :
November 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04911751
Start Date
November 8 2021
End Date
October 7 2024
Last Update
January 7 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Total Skin and Beauty Dermatology Center
Birmingham, Alabama, United States, 35205
2
Southern California Dermatology, Inc
Santa Ana, California, United States, 92701
3
Clinical Science Institute
Santa Monica, California, United States, 90404
4
Revival Research Institute
Doral, Florida, United States, 33122